• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics and Personalized Medicine >The AKR1D1*36 ( rs1872930 ) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome
【24h】

The AKR1D1*36 ( rs1872930 ) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome

机译：AKR1D1 * 36（rs1872930）等位基因变体与氯吡格雷治疗结果独立相关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: The present observational cohort study evaluated the association between the AKR1D1*36 (rs1872930) allele and the risk of major adverse cardiovascular and cerebrovascular events (MACCE) in clopidogrel treated patients. Methods: We screened 198 consecutive cardiovascular patients on clopidogrel therapy admitted in October to November 2010 with cardiovascular or cerebrovascular symptoms; of these 118 met the study protocol entry criteria; the median age of the cohort was 62.5 years (IQR 57–66 years), and 55% were females. Results: The median follow up time was 38.5 (IQR 24–48) months; Kaplan-Meier/Log-rank analysis showed that patients carrying the AKR1D1*36 allelic variant have a shorter event-free-survival compared to wild type patients, hazard ratio = 2.193 (95% CI, 1.091 to 4.406); p = 0.0155. Multivariable Cox regression analysis confirmed the AKR1D1*36 allele as an independent risk factor (HR = 2.36; 95% CI, 1.34 to 4.18) and identified 3 other risk factors for MACCE; previous percutaneous interventions (PCI), HR = 2.78; (95% CI, 1.34 to 5.78), and a history of myocardial infarction, HR = 2.62; (95% CI, 1.48 to 4.64) at baseline and the previously reported CYP2C19*2 polymorphism (HR = 2.33; 95% CI, 1.33 to 4.06). Conclusion: The AKR1D1*36 ( rs1872930 ) variant is independently associated with a higher risk for MACCE and shorter event-free survival time.
机译：目的：目前的观察性队列研究评估了氯吡格雷治疗的患者中AKR1D1 * 36（rs1872930）等位基因与重大不良心血管和脑血管事件（MACCE）风险之间的关联。方法：我们筛选了2010年10月至11月接受氯吡格雷治疗的198例心血管病患者，这些患者有心血管或脑血管症状。在这118个中，符合研究方案的入学标准;该队列的中位年龄为62.5岁（IQR 57-66岁），女性为55％。结果：中位随访时间为38.5（IQR 24-48）个月; Kaplan-Meier / Log-rank分析表明，与野生型患者相比，携带AKR1D1 * 36等位基因变异的患者的无事件生存期较短，危险比= 2.193（95％CI，1.091至4.406）。 p ＝ 0.0155。多变量Cox回归分析证实AKR1D1 * 36等位基因是一个独立的危险因素（HR = 2.36; 95％CI，1.34至4.18），并确定了MACCE的其他3个危险因素。既往经皮介入治疗（PCI），HR = 2.78; （95％CI，1.34至5.78），有心肌梗塞病史，HR = 2.62; （基线时为95％CI，1.48至4.64）和先前报道的CYP2C19 * 2多态性（HR = 2.33; 95％CI，1.33至4.06）。结论：AKR1D1 * 36（rs1872930）变体与MACCE的较高风险和较短的无事件生存时间独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号